查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1231389

卵巢癌症治疗药的全球市场 2023

Ovarian Cancer Therapeutics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

卵巢癌症治疗药的全球市场到2030年将达到205亿美元

在COVID-19后改变的商务环境中，2022年57亿美元的卵巢癌症治疗药的全球市场，在2022年～2030年间预计将以年复合成长率17.2％增长，到2030年达到205亿美元。本报告所分析的市场区隔之一的PARP抑制剂，年复合成长率将记录19.1％，到分析期间结束时达到128亿美元。考虑疫情后的復苏，血管新生抑制剂市场区隔今后8年的年复合成长率将修正为15％。

美国市场估算为16亿美元，中国则将以年复合成长率24.2％的速度成长预测

美国的卵巢癌症治疗药市场在2022年估算为16亿美元。作为世界第2大经济大国的中国，在2022年～2030年年复合成长率预计将为24.2％，到2030年达到55亿美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年间预计将各以11.3％和14.8％的速度成长。在欧洲市场中，德国以年复合成长率13.2％成长。

调查对像企业范例

  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • Clovis Oncology
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • MedImmune
  • Roche Diagnostics Corporation
  • Tesaro, Inc.

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美国家
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 其他中东
  • 非洲

第4章 竞争

简介目录
Product Code: MCP-1230

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Ovarian Cancer Therapeutics Market to Reach $20.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Ovarian Cancer Therapeutics estimated at US$5.7 Billion in the year 2022, is projected to reach a revised size of US$20.5 Billion by 2030, growing at aCAGR of 17.2% over the period 2022-2030. PARP Inhibitors, one of the segments analyzed in the report, is projected to record 19.1% CAGR and reach US$12.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Angiogenesis Inhibitors segment is readjusted to a revised 15% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 24.2% CAGR

The Ovarian Cancer Therapeutics market in the U.S. is estimated at US$1.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.5 Billion by the year 2030 trailing a CAGR of 24.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.3% and 14.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.2% CAGR.

Select Competitors (Total 12 Featured):

  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • Clovis Oncology
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • MedImmune
  • Roche Diagnostics Corporation
  • Tesaro, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Ovarian Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Ovarian Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Ovarian Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for PARP Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for PARP Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for PARP Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Angiogenesis Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Ovarian Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • JAPAN
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • CHINA
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: China 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • EUROPE
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Ovarian Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Ovarian Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • FRANCE
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: France 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • GERMANY
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Ovarian Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Ovarian Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • INDIA
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: India 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Ovarian Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Ovarian Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Ovarian Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Ovarian Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030
  • AFRICA
    • Ovarian Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Ovarian Cancer Therapeutics by Therapeutic Class - PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Ovarian Cancer Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for PARP Inhibitors, Angiogenesis Inhibitors and PD-L1 Inhibitors for the Years 2014, 2023 & 2030

IV. COMPETITION